A new benzodiazepine pharmacology.

By H. Möhler, J. Fritschy, U. Rudolph. Journal of Pharmacology and Experimental Therapeutics, 2002

706 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Cognitive Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1036f5b505aa93936afa5440472bdf4eef37ca29

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

In Cognitive Neuroscience

In Molecular Biology

Citations in the corpus

The endocannabinoid system controls key epileptogenic circuits in the hippocampus. (2006, neutral): “Benzodiazepines are allosteric modulators of GABA-A receptors that act as potent anticonvulsants by enhancing the inhibitory effects of GABAergic transmission (Möhler et al., 2002).”
Compensatory alteration of inhibitory synaptic circuits in cerebellum and thalamus of γ‐aminobutyric acid type A receptor α1 subunit knockout mice (2006, background): “…postsynaptic clustering -Aminobutyric acid type A (GABAA) receptors mediate the majority of inhibitory neurotransmission in the brain and represent major drug targets for the treatment of anxiety, sleep disorders, epilepsy, and muscle spasms (Mohler et al., 2002; Sieghart and Sperk, 2002).”
Model of autism: increased ratio of excitation/inhibition in key neural systems (2003, background): “Ongoing efforts are aimed at identifying novel benzodiazapines that can selectively activate distinct GABA A receptors, and therefore affect specific symptoms (Mohler et al. 2002).”
The biology of fear- and anxiety-related behaviors (2002, background): “Several GABAA receptor subtypes have been described.(96,97) The diazepam-sensitive α2-GABAA subtype appears to be specifically involved in anxiolysis.”
Expression of Distinct α Subunits of GABAA Receptor Regulates Inhibitory Synaptic Strength (2004, positive): “Given that the presence of 2 and 6 subunits has opposite actions on benzodiazepine sensitivity (Mohler et al. 2002; Olsen and MacDonald 2002), our data suggest that a developmental increase in the expression of both subunits but in different receptor subtypes occurs at CGC’s inhibitory synapses.”
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders (2005, background): “Recent advances in the molecular biology of the GABA A receptor complex have indicated that the sedation and memory impairment linked to benzodiazepine treatment are attributable to actions on α 1 -containing GABA receptor complexe”
Molecular and neuronal substrates for general anaesthetics (2004, neutral): “The subunit combinations α4β2γ/α4βnδ, α5β1/3γ2, α6β2/3γ2 and α6βnδ each represent less than 5% of all receptors in the brai”
Drugs for allosteric sites on receptors. (2014, background): “In addition to PAMs and NAMs, silent allosteric modulators (SAMs; also known as neutral allosteric ligands) bind at allosteric sites and can block the activity of PAMs and NAMs, yet they have no effect on orthosteric ligand responses (1-14).”
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders (2009, background): “Benzodiazepines provide an effective and safe approach to the treatment of anxiety and sleep disorders without inducing the potentially lethal effects of direct-acting GABA receptor agonist”